Abstract:The zinc-containing histone deacetylase enzyme HDAC7 is emerging as an important regulator of immunometabolism and cancer. Here, we exploit a cavity in HDAC7, filled by Tyr303 in HDAC1, to derive new inhibitors. Phenacetyl hydroxamates and 2-phenylbenzoyl hydroxamates bind to Zn2+ and are 50–2700-fold more selective inhibitors of HDAC7 than HDAC1. Phenylbenzoyl hydroxamates are 30–70-fold more potent HDAC7 inhibitors than phenacetyl hydroxamates, which is attributed to the benzoyl aromatic group interacting with Phe679 and Phe738. Phthalimide capping groups, including a saccharin analogue, decrease rotational freedom and provide hydrogen bond acceptor carbonyl/sulfonamide oxygens that increase inhibitor potency, liver microsome stability, solubility, and cell activity. Despite being the most potent HDAC7 inhibitors to date, they are not selective among class IIa enzymes. These strategies may help to produce tools for interrogating HDAC7 biology related to its catalytic site.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01967?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01967</a>.Additional experimental procedures, figures and tables describing modelling for alternative docked ligand poses in HDAC7, chemical synthesis, and compound characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_001.pdf">PDF</a>)Figure 3 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_002.pdb">PDB</a>)Figure 4 docking pose for compound 5a (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_003.pdb">PDB</a>)Figure 4 docking pose for compound 22 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_004.pdb">PDB</a>)Figure 4 docking pose for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_005.pdb">PDB</a>)Figure S1 docking pose for compound 5a (without water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_006.pdb">PDB</a>)Figure S1 docking pose for compound 5a (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_007.pdb">PDB</a>)Figure S2 docking pose for compound 15 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_008.pdb">PDB</a>)Figure S3 docking pose for compound 22 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_009.pdb">PDB</a>)Figure S3 docking pose for compound 30 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_010.pdb">PDB</a>)Figure S3 docking pose for compound 31 (with water) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_011.pdb">PDB</a>)SMILES strings of all compounds used for docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01967/suppl_file/jm0c01967_si_012.csv">CSV</a>)This article has not yet been cited by other publications.

Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized Zbg Features: A Case Study Using Histone Deacetylase 8

Identification of Ligand Features Essential for HDACs Inhibitors by Pharmacophore Modeling.

Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy

Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies

Crucial Structural Understanding for Selective HDAC8 Inhibition: Common Pharmacophores, Molecular Docking, Molecular Dynamics, and Zinc Binder Analysis of selective HDAC8 inhibitors

3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.

Discovery of Potent Selective HDAC6 Inhibitors with 5-Phenyl-1h-indole Fragment: Virtual Screening, Rational Design, and Biological Evaluation

Discovery of Potent Selective HDAC6 Inhibitors with 5-Phenyl-1 H-indole Fragment: Virtual Screening, Rational Design, and Biological Evaluation

Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy

Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays

The Discovery of Novel HDAC3 Inhibitors Via Virtual Screening and in Vitro Bioassay

Computational Exploration of Zinc Binding Groups for Hdac Inhibition

Discovery of Novel Metalloenzyme Inhibitors Based on Property Characterization: Strategy and Application for HDAC1 Inhibitors

Virtual screening and lead optimisation to identify novel inhibitors for HDAC-8

Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure–activity relationship (q-RASAR) and pharmacophore modeling

Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors.

HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates

Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation

Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning

Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via in silico approach and molecular modeling

Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor